Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse

Leukemia

Volumn 10, Issue 1, 1996, Pages 61-66

  Grimwade, D ^a,b   Howe, K ^a   Langabeer, S ^b   Burnett, A ^c   Goldstone, A ^b   Solomon, E ^a,d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF WALES   (United Kingdom)

^d Lincoln's Inn Fields   (United Kingdom)

Author keywords

Acute promyelocytic leukemia; Minimal residual disease; RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK;

EID: 0030061520     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia (letter). Lancet 1977; 1: 549-550.
2. Borrow J, Goddard AD, Sheer D, Solomon E Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577-1580.
3. de The H et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
4. Alcalay M et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA 1991; 88: 1977-1981.
5. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a novel zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991; 254: 1371-1374.
6. Kakizuka A et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
7. de Thé H et al. The PML-RARA alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell1991; 66: 675-684.
8. Kastner P et al. Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J 1992; 11: 629-642.
9. Dyck JA et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-343.
10. Weis K et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 1994; 76: 345-356.
11. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of promyelocytic leukemia cells in response to retinoic acid. Blood 1981; 57: 1000-1004.
12. Chomienne C et al. All-trans retinoic acid in acute promyelocytic leukemias: II. In vitro studies: structure function relationship. Blood 1990; 76: 1710-1717
13. Huang M-E et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
14. Castaigne S et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990; 76: 1704-1709.
15. Alcalay M et al. Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 4840-4844.
16. Borrow J et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992; 82: 529-540.
17. Nucifora G, Larson RA, Rowley JD. Persistance of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
18. Saunders MJ, Tobal K, Yin JAL. Detection of t(8;21) by reverse-transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk Res 1994; 18: 891-895.
19. Diverio D et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993; 82: 3556-3559.
20. Miller WH et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 1993; 82: 1689-1694.
21. Diverio D et al. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 1994; 8: 1105-1107.
22. Howe K et al. Polymerase chain reaction (PCR) analysis of bone marrow from patients with acute promyelocytic leukaemia (AML M3). Br J Haematol 1993; 84 (Suppl. 1): 26.
23. Korninger L et al. PML-RARΛ PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months. Br J Haematol 1994; 88: 427-431.
24. Lo Coco F et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
25. Miller WH et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-2698.
26. Fenaux P et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) followed by intensive chemotherapy (CT). Updated results of the European group. Blood 1994; 84 (Suppl. 1): 379a.
27. Pandolfi PP et al. Genomic variability and alternative splicing generate multiple PML/RAR-α transcripts that encode aberrant PML proteins and PML/RAR-α isoforms in acute promyelocytic leukemia. EMBO J 1992; 11: 1397-1407.
28. Linch DC et al. Acute promyelocytic leukaemia. Lancet 1994; 344; 1615-1618.
29. Tobal K, Saunders MJ, Grey MR, Yin JAL. Persistence of RARα-PML fusion mRNA detected by reverse-transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 1995, 90: 615-618.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
31. Lanotte M et al. NB4, a maturation inducible cell line with t(15,17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
32. Burnett AK. Karyotypically defined risk groups in acute myeloid leukaemia. Leuk Res 1994; 18: 889-890.
33. Avvisati G et al. AIDA protocol (all-trans retinoic acid + idarubicin) in the treatment of newly diagnosed acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Blood 1994; 84 (Suppl. 1): 380a.
34. Berger R et al. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities Genes Chromosomes Cancer 1991; 3: 332-337.
35. Huang W et al. Acute promyelocytic leukemia: clinical relevance of two major PML/RARα isoforms and detection of minimal residual disease by retro-transcriptase polymerase chain reaction to detect relapse. Blood 1993; 82: 1264-1269.
36. Vahdat L et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
37. Russell NH et al. Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk Lymphoma 1995; 16: 223-229.